Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.WT | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by jicoopon Apr 08, 2022 9:59am
219 Views
Post# 34587522

RE:The Data

RE:The Data
Sunvalley wrote:
 With regards to the 3.7% CR at 360 days and 450 days respectively , a shareholder friend  mentioned that those were not very good results for a CR after a year and thusly he is deterred from increasing his stock position. I could not argue with him and I was at a loss for a explanation as to how the Pending figure should factor into the equation. It seems that I am comfortable with the numbers in my head but I could not seem to explain it in laymans terms if you know what I mean. Does anyone have a simple way to explain this as I seem to have a mind block.?


Hey Sunvalley, I posted a lengthy explanation 3 days ago, giving my take on the numbers. here is a snipet from that, and you can forward to your shareholder firend if you like. 

Coop

The first scary number that jumps out is CR of 3.7 % , but what is that number really. In fact , it is 1 patient out of 27 presented as a percentage. The first BIG problem is that in fact, according to other numbers, only 9 patients have reached 450 days out, and if you redo the math, 1 patient in 9 is presented later on in the table under CR ( Evaluable patients ) with a number of 11.1 % . 

I think the 3.7% is misleading, as you cannot include them in final statistics if they have not reached the statistical endpoint. It's like a marathon of 27 runners, and only 1 of 9 known runners have finished, 8 did not make it, but therer are possibilities for others to make it all the way, so can you say only 1 in 27 have finised the race ? I think not .

Now back to that analogy, how many are still in race ? Well math tells me 18 others are still in the race, but not all will make it to the 450 day line succesfully ? How many have a chance ?  The pending column correctly show 66.7 % , which correponds to 18 out of 27 , but the real question then is how many make it to CR at 450 days from theat group. 

Now it gets a bit tricky, where do the other 18 stand ? My first take is that 18 patients have made it to 270 days, and 3 of them were CR at that point . How do I make that assumption, take the 27 totals patients, add the 3 from the 18 , and the one patient from the 9 group, and that gives you 4 patients total out of 27 reported at 270 days, which gives a 14.8 % , as you can see in the table in the 270 row under CR .

So how many of the 3 remaining have a chance to get CR at 450 . I beleive this number is 1 or 2 , a bit of a guess here I admit.

Hope this has not confused anyone further, but has helped at least expain the %'s a bit better . 
<< Previous
Bullboard Posts
Next >>